|Bid||7.00 x 900|
|Ask||8.55 x 2900|
|Day's Range||7.11 - 7.43|
|52 Week Range||7.11 - 29.34|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 16, 2022 - Mar 21, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.20|
Subscribe to Yahoo Finance Plus to view Fair Value for SQZLearn more
Bangor, ME, based Investment company Bangor Savings Bank (Current Portfolio) buys Vanguard Intermediate-Term Government Bond ETF, Global Payments Inc, Vanguard Tax-Exempt Bond ETF, International Business Machines Corp, Newell Brands Inc, sells Consumer Discretionary Select Sector SPDR, BP PLC, Philip Morris International Inc, Vanguard Intermediate-Term Corporate Bond ETF, iShares ESG Aware U.S.
WATERTOWN, Mass., January 06, 2022--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that John Maraganore, Ph.D., founding CEO of Alnylam Pharmaceuticals, has joined the company as a strategic advisor.
By John Vandermosten, CFA NYSE:SQZ READ THE FULL SQZ RESEARCH REPORT ESMO-IO Preliminary Results and Webcast/Conference Call SQZ Biotechnologies Company (NYSE:SQZ) hosted a webcast and conference call on December 9, 2021 to discuss updates to SQZ-PBMC-HPV-101 program at ESMO 1 Immuno-Oncology Congress 2021. SQZ-PBMC-HPV-101 is the company’s antigen presenting cell (APC) lead program. Jong Chul